These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 33899130)

  • 21. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Jacoby E; Bielorai B; Hutt D; Itzhaki O; Adam E; Bar D; Besser MJ; Toren A
    Br J Haematol; 2022 May; 197(4):475-481. PubMed ID: 35224724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
    Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
    [No Abstract]   [Full Text] [Related]  

  • 28. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
    Myers RM; Devine K; Li Y; Lawrence S; Leahy AB; Liu H; Vernau L; Callahan C; Baniewicz D; Kadauke S; McGuire R; Wertheim GB; Kulikovskaya I; Gonzalez VE; Fraietta JA; DiNofia AM; Hunger SP; Rheingold SR; Aplenc R; June CH; Grupp SA; Wray L; Maude SL
    Blood Adv; 2024 May; 8(9):2182-2192. PubMed ID: 38386999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.
    Maschan M; Caimi PF; Reese-Koc J; Sanchez GP; Sharma AA; Molostova O; Shelikhova L; Pershin D; Stepanov A; Muzalevskii Y; Suzart VG; Otegbeye F; Wald D; Xiong Y; Wu D; Knight A; Oparaocha I; Ferencz B; Roy A; Worden A; Kruger W; Kadan M; Schneider D; Orentas R; Sekaly RP; de Lima M; Dropulić B
    Nat Commun; 2021 Dec; 12(1):7200. PubMed ID: 34893603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation.
    Shang Q; Xue L; Lu A; Jia Y; Zuo Y; Zeng H; Zhang L
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):392-399.e5. PubMed ID: 38429221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia.
    Ma Y; Zhou H; Zhang J; Zhang Q; Li Y; Xie R; Zhang B; Shen Z; Li P; Liang A; Zhou K; Han L; Hu Y; Xu K; Sang W; Wang X
    Front Immunol; 2024; 15():1448709. PubMed ID: 39399502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
    Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
    Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation.
    Holland EM; Molina JC; Dede K; Moyer D; Zhou T; Yuan CM; Wang HW; Stetler-Stevenson M; Mackall C; Fry TJ; Panch S; Highfill S; Stroncek D; Little L; Lee DW; Shalabi H; Yates B; Shah N
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35534047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
    Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X
    Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
    Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
    Front Immunol; 2022; 13():879030. PubMed ID: 35558072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.
    Curran KJ; Margossian SP; Kernan NA; Silverman LB; Williams DA; Shukla N; Kobos R; Forlenza CJ; Steinherz P; Prockop S; Boulad F; Spitzer B; Cancio MI; Boelens JJ; Kung AL; Khakoo Y; Szenes V; Park JH; Sauter CS; Heller G; Wang X; Senechal B; O'Reilly RJ; Riviere I; Sadelain M; Brentjens RJ
    Blood; 2019 Dec; 134(26):2361-2368. PubMed ID: 31650176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.